MYRIAD GENETICS INC (MYGN)       19.51  -0.5 (-2.5%)

19.51  -0.5 (-2.5%)

US62855J1043 - Common Stock - After market: 19.51 0 (0%)

News Image
8 days ago - Myriad Genetics, Inc.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29,...

News Image
20 days ago - Myriad Genetics, Inc.

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care...

News Image
20 days ago - Myriad Genetics, Inc.

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care

News Image
23 days ago - Myriad Genetics, Inc.

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will...

News Image
a month ago - Myriad Genetics, Inc.

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT...

News Image
a month ago - The Motley Fool

Why Shares of Myriad Genetics Dropped 24% This Week

The genetic-testing company announced an acquisition and lowered its guidance.

News Image
a month ago - Myriad Genetics, Inc.

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced...

News Image
a month ago - Myriad Genetics, Inc.

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents...

News Image
a month ago - Myriad Genetics, Inc.

Myriad Genetics Reports Third Quarter Financial Results

Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses,...

News Image
a month ago - Myriad Genetics, Inc.

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced...

News Image
a month ago - Myriad Genetics, Inc.

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold...

News Image
2 months ago - MarketBeat

Is Illumina Still the Gamechanger in Genomics Sequencing?

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

News Image
2 months ago - Myriad Genetics, Inc.

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced...

News Image
3 months ago - Myriad Genetics, Inc.

Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama

La prueba EndoPredict de Myriad Genetics identificó con precisión a mujeres premenopáusicas con cáncer de mama ER+, HER2- que podrían evitar la...

News Image
3 months ago - Myriad Genetics, Inc.

Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa

O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com...